The hemoglobin levels are reportedly declining between parts of patients with thalassymia in Kerala even after blood transfusion, as leukocyte sets that are used to prevent adverse reactions are in deficiency.
Officials of the Council for the protection of patients with blood based on Kozhikoda, Kerala, also say that iron chelating drugs that are necessary to protect those who receive blood from iron overload are not available for about a year.
Thalassemia is a inherited blood disorder that is caused by the inability of the body to produce sufficient hemoglobin, a protein in red blood cells that transports oxygen from lungs to tissues and carbon dioxide. Available treatment includes regular blood transfusion and iron chelative therapy.
Less transfusion
Kareem Karassery, the President of the Council, says that most patients are aimed at taking blood transfusion because of the unavailability of leukocyte filters in hospitals and government hospitals. Although two units of blood are required to maintain hemoglobin levels, patients are considered to be only one fear of side effects. This reduces the levels of hemoglobin in their blood into an unusual situation, he says. “Also, a large amount of iron is also stored after blood transfusion. Due to the lack of iron cheling drugs, this would probably affect their heart, liver and other internal organs,” he says.
MCH response
According to sources, the government issued an order to the hospitals to go to a local purchase to make an influx of crisis. However, Mr. Karassery claims that the authorities ignore this directive and added that the district administration was submitted by a memorandum that emphasized their concern.
Resources at the Medical College Hospital (MCH), Kozhikode, say that steps are taken to resolve a shortage. They quote the financial crisis to which the government faces, for delaying new shares. The offers and fresh drug supply and a set of leukocyte filters were probably made available this week alone, adding.
Published – October 12, 2025 20:23
